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Abstract
Background: Symptomatic primary Epstein-Barr virus infection is a usually self-limiting illness in adolescents. We
present a case of an adolescent who had been receiving azathioprine for inflammatory bowel disease for four years
and developed a life-threatening primary Epstein-Barr virus infection successfully treated with rituximab.
Case presentation: An 11-year-old girl presented with chronic, bloody diarrhea. Endoscopic biopsies confirmed a
diagnosis of chronic ulcerative colitis with features of Crohn’s disease. Azathioprine was initiated after one year due
to active colitis. She responded well and remission was achieved. At the age of 16 years she developed a life-
threatening Epstein-Barr virus infection including severe multiple organ failure and was critically ill for 4 weeks in
the intensive care unit. Natural killer cells were virtually absent in the lymphocyte subset analysis. Azathioprine was
stopped on admission. She was initially treated with corticosteroids, acyclovir and intravenous immunoglobulin.
Approximately 30 days after admission, she developed signs of severe hepatitis and pneumonitis and received
weekly rituximab infusions for 8 weeks. Primary immunodeficiency was excluded by whole exome sequencing in
two independent laboratories. Persistent viremia stopped when the natural killer cell count started to rise,
approximately 90 days after the cessation of azathioprine.
Conclusions: We found 17 comparable cases in the literature. None of the previous cases reported in the literature,
who had been treated with azathioprine and developed either a severe or a fatal Epstein-Barr virus infection,
underwent full genetic and prospective immunological workup to rule out known primary immunodeficiencies.
Recently, azathioprine has been shown to cause rather specific immunosuppression, resulting in natural killer cell
depletion. Our case demonstrates that slow recovery from azathioprine-induced natural killer cell depletion,
3 months after the stopping of azathioprine, coincided with the clearance of viremia and clinical recovery. Finally,
our choice of treating the patient with rituximab, as previously used for patients with a severe immunosuppression
and Epstein-Barr virus viremia, appeared to be successful in this case. We suggest testing for Epstein-Barr virus
serology before starting azathioprine and measuring natural killer cell counts during the treatment to identify
patients at risk of developing an unusually severe primary Epstein-Barr virus infection.
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Background
Symptomatic primary Epstein-Barr virus (EBV) infection
is a usually self-limiting illness presenting with fever,
lymphadenitis, tonsillitis, hepatitis, and splenomegaly in
adolescents and young adults. The duration of EBV
viremia during primary EBV infection is rather short,
while the median half-time for viral elimination is three
days [1]. It is well known that after organ or allogenic
hematopoietic stem cell transplantation (HSCT), or in
patients with primary immunodeficiency, EBV primary
infection or reactivation can cause uncontrolled and
severe infection and lymphoproliferation. We present a
case of an adolescent who had been receiving azathio-
prine for inflammatory bowel disease for four years who
developed a life-threatening EBV infection. In addition,
we performed a systematic review of the literature on
azathioprine and EBV infection.
Case presentation
Methods
We first followed our patient up closely during severe
EBV infection using repeated flow cytometry measure-
ments to detect all lymphocyte subpopulations, including
natural killer (NK) cell counts. The EBV viral load was
measured using a quantitative nucleic acid amplification
test (Fig. 1). Immunoglobulin (Ig) M antibodies against
viral capsid antigen (VCA) and IgG antibodies to EBV nu-
clear antigen (EBNA) were measured. Whole exome
sequencing (WES) was performed in two independent la-
boratories, the Institute for Molecular Medicine, Helsinki,
Finland, as previously described [2], and Centogene,
Germany (www.centogene.com), in order to detect any
known primary immunodeficiency. Both the patient and
her mother gave their written informed consent to the
publication of this case history. We then performed a sys-
tematic literature search via PubMed in December 2016
using the terms “Epstein-Barr virus” and “azathioprine”. A
total 154 possible papers were identified for review, of
which 13 were retrieved for detailed examination.
The patient
An 11-year-old girl presented with chronic, bloody
diarrhea. Endoscopic biopsies confirmed a diagnosis of
chronic ulcerative colitis with features of Crohn’s
disease. She was treated first with prednisolone and
mesalazine, but azathioprine, 75 mg/day (2.5 mg/kg), was
started after one year on account of continued active
colitis. She responded well to this and remission was
achieved. At the age of 16 years she was admitted to
hospital on account of a high fever and poor general
condition. Azathioprine was stopped on account of
acute infection, as three-lineage cytopenia was de-
tected on admission: her white blood cell count was
2.5 (4.5–11 × 109/L), platelets 38 (200–450 × 109/L)
and hemoglobin 89 g/L (117–155 g/L). Splenomegaly,
acute cardiac failure and acute hepatic failure, with
Fig. 1 Epstein-Barr viremia and NK-cell counts after admission in a critically ill adolescent with a primary EBV infection and previously treated with
azathioprine for inflammatory bowel disease. Azathioprine was stopped on day 1. NK-cell counts started to rise after 90 days and were normal
after 120 days, coinciding with clearance of the viremia. During the course of illness, CD8+ T-cell counts were 1131 (220–1129 × 106/L) on day 32,
2535 on day 70, 2487 on day 93 and 2537 on day 106
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15% necrosis in a biopsy, were observed in the next
few days. Symptoms of encephalitis were present, but
a brain MRI was normal. Viral genome examinations
by EBV polymerase chain reaction revealed > 350,000
copies/mL in plasma on admission and > 1 million
copies/mL after 4 days of treatment (Fig. 1). A high
viral load of > 8 million copies/mL was also detected
in the liver biopsy specimen. Tests for IgM antibodies
to VCA were positive on admission, whereas IgG
antibodies to EBNA were negative, indicating acute
EBV infection. She was treated once with rituximab
and then with corticosteroids, acyclovir and intraven-
ous immunoglobulin. She developed severe multiple
organ failure, including cardiac, hepatic and respira-
tory failure, and was critically ill for 4 weeks in the
intensive care unit. After this treatment in the inten-
sive care unit, approximately 30 days after admission,
the viral load started to increase again and she devel-
oped signs of severe hepatitis and pneumonitis, so
that regular weekly rituximab infusions were given for
a total of 8 weeks. Very low NK-cells were noted and
the persistent viremia (detection level 300 copies/mL)
stopped when the NK-cell count started to rise, ap-
proximately 90 days after the cessation of azathioprine
(Fig. 1). During the course of illness, CD8+ T-cell
counts were 1131 (220–1129 × 106/L) on day 32, 2535
on day 70, 2487 on day 93 and 2537 on day 106. Due
to the prolongation of viremia and hepatitis despite
the discontinuation of azathioprine, WES was per-
formed. This did not reveal any known primary im-
munodeficiency, but the patient was found to be
carrying two rare heterozygous variants of the TLR3
and OAS1 genes, in which variants have previously
shown to be associated with susceptibility to viral
infections. TPMT genotype leading to low enzyme
activity was excluded in this case after the patient’s
recovery. A high total IgG level (> 15 g/L) persisted
for 6 months after clearance of the viremia, and the
low CD19-cell count attributable to the rituximab
treatment started to rise 6 months after cessation of
the infusions. At the last follow-up visit, she was
asymptomatic and healthy and had successfully
returned to her studies 6 months after the onset of
the EBV infection. She was still in remission with
respect to her inflammatory bowel disease without
any medication.
Systematic review of the literature
Examination of the 13 relevant publications yielded a
total of 17 corresponding cases, mainly of adolescents or
young adults with Crohn’s disease or ulcerative colitis
who had been treated with azathioprine and developed
either severe or fatal EBV infections, or EBV-driven
hemophagocytic lymphohistiocytosis or some other
lymphoproliferative disorder, excluding lymphomas [3–
15]. Four patients had died [4, 7, 10, 14]. High EBV
viremia (> 100,000 copies/mL) was documented in five
patients [3, 7, 10–12]. NK-cell counts had been made in
two out of the 17 patients and either a low count or low
NK-cell cytotoxicity had been noted during the acute
phase of the illness in both patient cases [3, 13]. CD8+
T-cell counts of the patients were not reported in the lit-
erature. Three patients had been successfully treated with
repeated rituximab infusions [3, 8, 11]. Most patients had
received corticosteroids and also acyclovir or ganciclovir.
X-linked lymphoproliferative disease (XLP) was excluded
in two male patients by genetic testing [7, 10].
Discussion and conclusions
Azathioprine is widely used for the treatment of Crohn’s
disease and ulcerative colitis. Our case and systematic
literature search confirm that a primary EBV infection
can be extremely severe or even fatal for EBV-negative
adolescents or young adults receiving azathioprine.
Azathioprine has recently been shown to cause rather
specific immunosuppression, resulting in NK-cell [16, 17],
but not T-cell depletion [17]. Moreover, early-differenti-
ated NK-cells seem to be critical in the immune control of
primary EBV infection as this subset of NK-cells expands
and restricts lytic EBV infection that is poorly controlled
in infectious mononucleosis [18, 19]. We repeatedly moni-
tored our patient’s lymphocyte subpopulation count using
flow cytometry and noted an almost total loss of the
NK-cell population, whereas the number of CD8+ T-cells
were within the normal range. We were thus able to draw
a clear time series showing that the clearance of EBV
viremia coincided with the normalization of NK-cell
counts three to four months after ceasing to administer
azathioprine. This supports the idea that azathioprine
caused a severe secondary immunodeficiency and a lack
of NK-cells, resulting in an uncontrolled EBV infection
and hyperinflammation, since NK-cells play a role in
down-regulating inflammatory responses [20]. Thus the
phenotype observed in our patient mimics the known
pathomechanism of congenital hemophagocytic lympho-
histiocytosis, which is a hyperinflammatory condition ex-
plained by low cytotoxic functioning of the NK-cells or
T-cells on account of genetic defects [20]. The risk of
hemophagocytic lymphohistiocytosis in children with
Crohn’s disease, often treated with thiopurines, has been
estimated to be 100-fold in a population-based patient
series of 5 cases with HLH and inflammatory bowel dis-
ease [4]. The risk of lymphoproliferative disorders, includ-
ing lymphomas, has been reported in a large cohort of
inflammatory bowel disease patients to be five-fold in
those patients receiving thiopurines [21]. Our findings
offer a possible explanation for this observed epidemio-
logical risk.
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Corticosteroids and acyclovir are recommended for the
treatment of severe EBV infection. After an organ or HSCT
EBV is known to cause a lymphoproliferative disorder
which can be treated with rituximab, an anti-CD20 mono-
clonal antibody, in order to reduce B-cells and stop viremia,
since B-cells are the main replication site of Epstein-Barr
viruses during infection. In patients with XLP, a primary
immunodeficiency leading to uncontrolled EBV infection,
severe EBV infection has recently been treated with rituxi-
mab before HSCT. We chose to treat our patient with cor-
ticosteroids, acyclovir and one dose of rituximab at the
onset of the disease. However, as the EBV viral load started
to increase again after 1month despite corticosteroid and
acyclovir therapy and she simultaneously developed new
signs of severe pneumonitis and hepatitis, we decided to
administer rituximab weekly until viremia had been
arrested, three months after admission. Donor-derived
EBV-specific cytotoxic T-cells are a novel experimental
treatment for uncontrolled EBV infections in patients with
primary or secondary immunodeficiency [22], and we con-
sequently considered treating our patient with EBV-specific
cytotoxic T-cells before she started to respond well to ritux-
imab treatment.
The previous cases reported in the literature had not
undergone thorough WES to rule out undiagnosed
known primary immunodeficiencies, and even though
XLP was not a diagnostic alternative for a female pa-
tient, defects in the ITK, STK4, TNFRSF7 and CORO1A
genes, for instance, can lead to a life-threatening EBV
infection. If a primary immunodeficiency had been
diagnosed, the patient could have been considered for
treatment with EBV-specific cytotoxic T-cells as a bridge
before HSCT. Rapid WES is thus a very useful diagnos-
tic tool in cases of unusually severe EBV infection, in
order to exclude primary immunodeficiencies, as these
need to be treated with a prompt HSCT.
Our clinical case demonstrates that azathioprine-in-
duced NK-cell depletion could be the reason for a severe,
life-threatening primary EBV infection in this context.
Achieving immune reconstitution may take several
months after the cessation of azathioprine medication. All
infectious disease specialists treating adolescents and
young adult patients who have been receiving azathioprine
should be aware of the risk. Testing for EBV serology be-
fore starting azathioprine could help to identify
EBV-seronegative adolescents and young adults who
might have a high risk of developing an unusually severe
primary infection.
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